

Immediate Release

CordLife First in Hong Kong to Implement World's Most Preferred Automated Cord Blood Processing

- The world's most recognised and widely adopted automated cord blood processing technology, Sepax[®] is now available in Hong Kong.
- CordLife is the first and only private cord blood bank in the territory to offer Sepax[®].

HONG KONG, 6th February 2009 – Technology pioneer and cord blood banking giant CordLife Ltd (ASX: CBB) today announced that it will implement Sepax[®], the world's most recognised and widely adopted automated cord blood processing system in Hong Kong. CordLife is the first and only private cord blood bank in the territory to offer the FDA-cleared technology which can harvest significantly higher numbers of stem cells from cord blood.

“As a technology pioneer, we are continually pursuing proven advanced technologies which will enhance our clients' stem cells as potential source material for lifesaving treatment. Sepax[®] has been proven to harvest the highest number of stem cells, compared to other processing methods in the industry. If ever needed, a higher number of stem cells will improve the rate of transplant success. At the same time, families will also have greater access and flexibility to use these cells for other potential cellular therapies,” said Steven Fang, Group CEO of CordLife.

“We are optimistic that this latest technology will be well received in Hong Kong because it will be worth so much more should your family member ever need it. We will make it available, as affordable as before,” said Ms Emily Cheung, General Manager of CordLife Hong Kong.

To date, over 400,000 cord blood units in 40 countries were processed using Sepax[®], making it almost a standard for the processing of cord blood today. It is also accredited by numerous health ministries worldwide including Japan, the European Union, Canada and Australia, to name a few. Known for its Swiss made accuracy, Sepax[®] is compliant with both AABB (formerly American Association of Blood Banks) and FACT Netcord, which are global standards for cord blood banking.

###

About CordLife

CordLife operates the world's largest network of private cord blood banks with full processing and cryopreservation storage facilities in Singapore, Australia, Hong Kong, Indonesia and India as well as marketing presence in Asia. The first cord blood bank to be set up in Singapore, and among the first in Asia, CordLife's state-of-the-art facility is the first and only private cord blood bank in Southeast Asia to be accredited by AABB. CordLife was awarded the prestigious "Technology Pioneer 2007" by the Geneva-based World Economic Forum; the only one of 3 companies in Asia from a pool of 225 world nominees. CordLife is listed on the Australian Stock Exchange, under the symbol, CBB. For more information, please visit www.cordlife.com.

About Sepax[®]

Specially invented nine years ago to ensure smooth and precise cell separation without operator intervention – Sepax[®] significantly reduces risk of cross contamination as well as operator error. The processing step is one of the most important and involves separating the stem cells from the other components, such as red blood cells and plasma. During this separation procedure, the cord blood is spun to create a centrifugal force that separates the components based on their density. Previously, this procedure was performed manually using a transfer set, syringes and a centrifuge. For the last few years, there has been a move in both public and private banks to standardise this process through automation and today a large majority of the top banks around the world use Sepax[®] as the reference cord blood processing technology. For more information, please visit www.processedbysepax.com.

About Biosafe SA

Biosafe is the industry standard in automated adult stem cell processing and a leader in the expansive field of regenerative medicine. With the proprietary Sepax[®] technology, Biosafe offers the only fully automated solution in adult stem cell processing and has become the system of reference for the majority of leading cord blood banks worldwide. Biosafe is a U.S. FDA registered medical device manufacturer as well as an ISO 9001:2000 and ISO 3485:2003 certified company. For more information, please visit www.processedbysepax.com.

For more information, please contact:

Steven Fang, CEO, CordLife Limited

Tel: +61 (0)3 9642 5580

Mob: +61 (0)400 933 243

Email: sfang@cordlife.com

Cynthia Chow, Marketing Manager, CordLife Hong Kong

Tel: +852 2511 8881

Mob: +852 9400 2400

Email: cynthia.chow@cordlife.com